Complications and severity of COVID-19 in patients with head and neck cancer (HNC): A COVID-19 and Cancer Consortium (CCC19) registry analysis.

Authors

Vidhya Karivedu

Vidhya Karivedu

Division of Medical Oncology, Ohio State University, Columbus, OH

Vidhya Karivedu , Chih-Yuan Hsu , John F. Deeken , Sachin R Jhawar , Daniel G. Stover , Daniel W. Bowles , Clara Hwang , Rana R. McKay , Erika Ruiz-Garcia , Ziad Bakouny , Arielle Sabbah , Elizabeth Klein , Peter Paul Yu , Michael Glover , Michael Wotman , Eric B. Durbin , Amit Kulkarni , Sibel Blau , Sigrun Hallmeyer , Trisha Michel Wise-Draper

Organizations

Division of Medical Oncology, Ohio State University, Columbus, OH, Vanderbilt University Medical Center, Nashville, TN, Inova Schar Cancer Institute, Fairfax, VA, The Ohio State University Wexner Medical Center, Columbus, OH, The Ohio State University Comprehensive Cancer Center, Columbus, OH, Division of Medical Oncology, University of Colorado Cancer Center, Aurora, CO, Henry Ford Health System, Detroit, MI, University of California San Diego Health, La Jolla, CA, Instituto Nacional de Cancerologia, Mexico City, Mexico, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, McGill, Montreal, QC, Canada, The Warren Alpert Medical School of Brown University and Lifespan Cancer Institute, Providence, RI, Hartford HealthCare Cancer Institute, Hartford, CT, Stanford University Medical Center, Stanford, CA, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, Kentucky Cancer Registry, Lexington, KY, University of Minnesota, Minneapolis, MN, Rainier Hematology Oncology/Northwest Medical Specialties, Seattle, WA, Oncology Specialists, SC, Park Ridge, IL, University of Cincinnati Cancer Center, Cincinnati, OH

Research Funding

Other

Background: Patients with cancer have worse outcomes from COVID-19 infection. However, the specific impact of COVID-19 on patients with head and neck cancer (HNC) is largely unknown. The COVID-19 and Cancer Consortium (CCC19) maintains an international registry (NCT04354701) aimed to investigate the clinical course and complications of COVID-19 in patients with cancer. Here, we report severity of COVID-19 and its complications among HNC patients. Methods: The CCC19 registry was queried for patients with HNC and laboratory confirmed SARS-CoV-2 infection. The co-primary outcomes were severity of COVID-19 illness on an ordinal scale (0: no complications; 1: hospitalized, no oxygen (O2); 2: hospitalized, required O2; 3: ICU admission; 4: mechanical ventilation (MV); 5: death), and severity of complications (mild, moderate, serious). The outcomes were further stratified by demographics, recent treatment (systemic vs local; surgery, radiation (RT) vs systemic), treatment intent (palliative vs curative), and cancer status (remission, responding, stable, progressing). Results: From March 2020 to December 2021, 356 HNC patients were identified. Median age was 65 (interquartile range 58-74), 29% were female, 56% were white, 67% were former or current smokers, 20% had a BMI >30, 15% had an ECOG performance status >2, and 57% had >2 comorbidities. 154 (43%) had no complications, 61 (17%) were hospitalized without O2, 135 (38%) were hospitalized with O2, 50 (14%) required ICU, 32 (9%) required MV, and 74 (21%) died. 88 (25%) had mild, 59 (17%) had moderate, and 132 (37%) had serious complications. 33% of patients who received systemic therapy and 30% who received RT within 3 mo prior to COVID-19 diagnosis died. Mortality was higher in patients receiving palliative when compared to curative intent treatment (44% vs 16%). In addition, 50% of patients with actively progressing cancer, and 45% who had serious complications died. Importantly, 37 (n=12 palliative systemic therapy and n=25 local therapy) patients had a treatment delay due to COVID-19 diagnosis. Conclusions: Our study is the largest cohort to date describing COVID-19 outcomes in HNC patients and suggest a high rate of mortality even in those receiving local and curative intent treatment. Variables stratified by COVID-19 severity. Note: Ordinal levels 3 and 4 not shown due to small case numbers.

Characteristics
Worst severity of COVID-19 illness
0

(N=150)

%
1

(N=51)

%
2

(N=60)

%
5

(N=74)

%
Complication severity

Mild

Moderate

Serious


84

25

<3


10

37

<10


<8

27

8


<7

8

45
ECOG>2
15
<10
19
52
Obesity (BMI >30)
49
10
25
10
Smoking

Never

Former/current


49

38


12

16


14

19


19

21
Treatment intent

Curative

Palliative


48

25


16

15


19

15


16

44
Treatment modality

Systemic therapy

Local therapy


34

30


19

10


11

28


33

27
Cancer status

Remission/NED

Responding/stable

Progressing


50

39

25


12

18

14


18

24

<8


12

16

50

Note: Ordinal levels 3 and 4 not shown due to small case number

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 6031)

DOI

10.1200/JCO.2022.40.16_suppl.6031

Abstract #

6031

Poster Bd #

23

Abstract Disclosures